Bulk Pharmaceutical API Sources for ISOVUE-370

Bulk Pharmaceutical API Sources for ISOVUE-370

Vendor	Vendor Homepage	Vendor Sku	API Url
Molport		MolPort-003-848-224
Amadis Chemical		A834067
AKos Consulting & Solutions		AKOS015891034

ISOVUE-370 Bulk Active Pharmaceutical Ingredient (API) Sourcing

Last updated: February 19, 2026

This report details critical considerations for sourcing bulk Active Pharmaceutical Ingredient (API) for ISOVUE-370, a non-ionic iodinated contrast medium used in medical imaging. Sourcing requires stringent adherence to regulatory standards, quality control, and supply chain reliability to ensure patient safety and product efficacy.

What is ISOVUE-370 and its API?

ISOVUE-370 is a registered trademark for a non-ionic, low-osmolality iodinated contrast agent. The API is Ioversol. Ioversol is a triiodinated benzene derivative that acts as a radiopaque agent, meaning it absorbs X-rays more effectively than surrounding tissues, thereby enhancing the visibility of anatomical structures or physiological processes during diagnostic imaging procedures. Its low osmolality minimizes adverse physiological effects compared to older ionic contrast agents.

Regulatory Landscape for Ioversol API

The manufacturing and sourcing of pharmaceutical APIs, including Ioversol, are subject to extensive regulatory oversight by health authorities worldwide. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Manufacturers must comply with Current Good Manufacturing Practices (cGMP) as outlined in 21 CFR Parts 210 and 211. Drug Master Files (DMFs) are required for APIs, detailing the manufacturing process, controls, and quality attributes. Site inspections are a routine part of FDA oversight.
• European Medicines Agency (EMA): Compliance with EudraLex Volume 4, Part II (Good Manufacturing Practice for Active Substances used as Starting Materials) is mandatory. Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) are often utilized to demonstrate compliance.
• Other National Regulatory Authorities: Health Canada, Japan's Pharmaceuticals and Medical Devices Agency (PMDA), and others have comparable cGMP requirements and API documentation expectations.

Compliance with these regulations ensures the API's identity, strength, quality, and purity.

Key Quality Attributes of Ioversol API

The quality of Ioversol API is paramount and is defined by several critical attributes, typically detailed in pharmacopoeial monographs and manufacturer specifications.

• Purity: High purity is essential to minimize potential adverse reactions. Specifications often demand purity levels exceeding 99.0% (on an anhydrous basis). Impurities, including related substances and residual solvents, are strictly controlled.
  • Related Substances: Limits are set for specific known impurities (e.g., isomers, degradation products) and for total unspecified impurities. These are typically quantified using High-Performance Liquid Chromatography (HPLC).
  • Residual Solvents: Solvents used during the synthesis must be controlled to acceptable limits (ICH Q3C guidelines). Common solvents may include methanol, ethanol, and isopropanol, with specific ppm limits.
• Identity: Confirmatory tests are required to ensure the API is indeed Ioversol. Techniques include Infrared (IR) spectroscopy, Nuclear Magnetic Resonance (NMR) spectroscopy, and elemental analysis for iodine content.
• Assay: The quantitative determination of Ioversol content. This is typically performed by HPLC or titration and must fall within a defined range, often 98.0% to 102.0% (on an anhydrous, solvent-free basis).
• Water Content: Controlled to prevent degradation and ensure consistent API properties. Karl Fischer titration is the standard method, with limits typically below 0.5%.
• Heavy Metals: Limits are imposed to prevent toxicity, usually not exceeding 10 ppm or 20 ppm.
• Endotoxins: For injectable APIs, endotoxin levels must be extremely low to prevent pyrogenic reactions. The Limulus Amebocyte Lysate (LAL) test is commonly employed.
• Particle Size Distribution (PSD): While less critical for soluble APIs like Ioversol compared to solid dosage forms, PSD can influence dissolution rates and handling properties during formulation. Specifications, if present, would be defined by the formulator.
• Appearance: The API should typically be a white or almost white crystalline powder.

Ioversol Synthesis and Manufacturing Considerations

Ioversol (3,5-bis(acetylamino)-2,4,6-triiodobenzoic acid) is synthesized through a multi-step chemical process involving iodination of a benzoic acid derivative. Key considerations in manufacturing include:

• Starting Materials and Intermediates: The quality and consistency of raw materials and key intermediates directly impact the final API quality. Robust supplier qualification and incoming material testing are crucial.
• Reaction Control: Precise control of reaction conditions (temperature, pressure, pH, reaction time) is vital for achieving high yields and minimizing byproduct formation.
• Purification: Multiple purification steps, often involving recrystallization, are employed to remove impurities and achieve the required pharmaceutical grade. The choice of solvents and crystallization conditions are critical.
• Drying and Milling: Drying must be controlled to achieve the specified water content without degradation. Milling may be used to achieve a desired particle size, though Ioversol is typically formulated in solution.
• Process Validation: The entire manufacturing process must be validated to demonstrate reproducibility and consistent product quality batch after batch.
• Change Control: Any changes to the manufacturing process, equipment, or raw materials must be rigorously managed through a formal change control system and may require regulatory notification or approval.

Global Ioversol API Manufacturers

The production of complex APIs like Ioversol is concentrated among specialized chemical manufacturers. Identifying reliable sources involves assessing their regulatory compliance, manufacturing capacity, quality systems, and track record.

Several companies globally are known to produce or have the capability to produce Ioversol API. These often include:

• Bracco Imaging S.p.A.: As the originator of ISOVUE, Bracco is a primary manufacturer and has robust internal production capabilities.
• Other Contract Manufacturing Organizations (CMOs) and API Specialists: Companies specializing in complex organic synthesis and API production, often with FDA and EMA-approved facilities, may also produce Ioversol. These could include:
  • Taj Pharmaceuticals: (Note: Verification of current Ioversol production status is recommended.)
  • Loba Chemie: (Note: Primarily a laboratory reagent supplier, but may have custom synthesis capabilities for APIs.)
  • Specialized Fine Chemical Manufacturers: Companies in India, China, and Europe with expertise in iodinated compounds and cGMP compliance.

Due diligence is essential when identifying and qualifying new API suppliers. This includes:

• Regulatory Filings: Reviewing publicly available DMFs (e.g., FDA DMFs) or requesting access to proprietary documentation.
• Site Audits: Conducting thorough on-site audits of manufacturing facilities to assess cGMP compliance, quality systems, and operational procedures.
• Quality Agreements: Establishing comprehensive quality agreements that define roles, responsibilities, and expectations for quality control and assurance.
• Sample Testing: Independently testing API samples from prospective suppliers to verify conformance to specifications.
• Supply Chain Security: Assessing the supplier's supply chain resilience, geopolitical risks, and business continuity plans.

Supply Chain Risks and Mitigation Strategies

Sourcing bulk API for a critical drug like ISOVUE-370 involves inherent supply chain risks.

• Geopolitical Instability: Concentration of manufacturing in certain regions can expose supply chains to disruptions from political unrest, trade disputes, or natural disasters.
  • Mitigation: Diversify sourcing across different geographical regions and suppliers where feasible. Maintain safety stock.
• Regulatory Changes: Evolving cGMP requirements or new impurity control mandates can necessitate process changes or revalidation efforts.
  • Mitigation: Maintain close communication with regulatory bodies and stay informed about evolving guidelines. Proactively engage suppliers on potential future requirements.
• Quality Deviations: Batch failures, contamination events, or process drifts can lead to supply interruptions and costly recalls.
  • Mitigation: Implement stringent supplier qualification programs, robust quality agreements, and continuous monitoring of supplier performance. Conduct regular audits.
• Intellectual Property (IP) and Patent Expirations: While Ioversol itself may be off-patent for composition of matter, manufacturing processes, polymorphs, or specific formulations may still be protected.
  • Mitigation: Conduct thorough IP landscape analysis to ensure freedom to operate. Secure licenses or engage suppliers with verified freedom to supply.
• Capacity Constraints: Over-reliance on a single supplier or a supplier with limited capacity can create bottlenecks, especially during periods of high demand.
  • Mitigation: Qualify multiple suppliers and understand their production capacities. Consider long-term supply agreements with committed volumes.
• Raw Material Sourcing: The supply of critical starting materials and reagents for Ioversol synthesis can itself be a point of vulnerability.
  • Mitigation: Require API manufacturers to have robust control over their own upstream supply chains, including qualifying their key raw material suppliers.

Cost Considerations for Ioversol API

The cost of Ioversol API is influenced by several factors:

• Manufacturing Complexity: The multi-step synthesis and stringent purification requirements contribute to higher production costs.
• Raw Material Costs: The price and availability of key iodinated intermediates and reagents are significant drivers.
• Regulatory Compliance: Investments in cGMP-compliant facilities, quality systems, and documentation are factored into pricing.
• Economies of Scale: Larger production volumes generally lead to lower per-unit costs.
• Supplier Location and Labor Costs: Regional differences in labor and operational expenses play a role.
• Negotiated Agreements: Contract terms, volume commitments, and long-term partnerships can influence pricing.

Manufacturers typically provide pricing based on quantity, contract duration, and Incoterms (e.g., Ex Works, CIF). Fluctuations in global commodity prices, particularly for iodine derivatives, can impact API pricing.

Key Takeaways

• Ioversol API sourcing demands adherence to stringent global cGMP regulations, primarily from the FDA and EMA.
• Critical quality attributes include high purity, controlled impurity profiles, and validated identity and assay.
• Manufacturers must demonstrate robust quality management systems, process validation, and change control procedures.
• Diversification of suppliers across different geographic regions is a key strategy to mitigate supply chain risks.
• Comprehensive due diligence, including site audits and review of regulatory filings, is essential for supplier qualification.
• Supply chain resilience strategies should address geopolitical stability, regulatory changes, and capacity constraints.
• API cost is influenced by manufacturing complexity, raw material prices, regulatory overhead, and economies of scale.

FAQs

1. What is the primary regulatory filing required for Ioversol API in the U.S.? A Drug Master File (DMF) is required for Ioversol API submitted to the U.S. Food and Drug Administration (FDA).

2. How is the purity of Ioversol API typically assessed? Purity of Ioversol API is typically assessed using High-Performance Liquid Chromatography (HPLC) to quantify the main compound and detect/quantify related substances and impurities.

3. What are the main risks associated with sourcing Ioversol API from a single supplier? The primary risks include supply chain disruption due to the supplier's operational issues, regulatory non-compliance, geopolitical events, or capacity limitations.

4. Are there specific pharmacopoeial monographs that define the quality standards for Ioversol? Yes, Ioversol is described in pharmacopoeias. For example, the European Pharmacopoeia (Ph. Eur.) and potentially the United States Pharmacopeia (USP) would have monographs if Ioversol is a recognized API.

5. What is the significance of low osmolality for Ioversol? The low osmolality of Ioversol, compared to older ionic contrast agents, significantly reduces the risk of adverse physiological reactions such as osmotic diuresis, vein irritation, and discomfort for the patient.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) for Finished Pharmaceuticals. Retrieved from [FDA Website - relevant cGMP sections] [2] European Medicines Agency. (2010). EudraLex The Rules Governing Medicinal Products in the European Union Volume 4 Good Manufacturing Practice Medicinal Products Part II: Basic Requirements for Active Substances used as Starting Materials. Retrieved from [EMA Website - EudraLex Volume 4] [3] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (1997). Impurities: Guideline for Residual Solvents Q3C(R4). [4] Bracco Imaging S.p.A. (n.d.). Product Information - ISOVUE. Retrieved from [Bracco Imaging Website]